(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Key Inclusion Criteria:

1. Histologically confirmed locally advanced, metastatic, and/or unresectable GIST.Molecular pathology report must be available for Part 2; if molecular pathologyreport is unavailable or inadequate, an archival or fresh tumor tissue sample willbe required to evaluate mutational status prior to randomization.

2. Documented disease progression on or intolerance to imatinib

3. Subjects must have received the following treatment: DDI Substudy/Part 1a: Treatment with ≥1 prior lines of therapy for GIST Part 1b:Treatment with ≥2 prior TKI for GISTs Part 2: Prior treatment with imatinib only

4. Have at least 1 measurable lesion according to mRECIST v1.1 (Part1a, Part 1b, Part

5. ECOG - 0 to 2

6. Have clinically acceptable local laboratory screening results (clinical chemistryand hematology) within certain limits

Key Exclusion Criteria:

1. Known PDGFR driving mutations or known succinate dehydrogenase deficiency

2. Clinically significant cardiac disease

3. Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of studydrug

4. Gastrointestinal abnormalities including, but not limited to, significant nausea andvomiting, malabsorption, external biliary shunt, or significant bowel resection thatwould preclude adequate absorption

5. Any active bleeding excluding hemorrhoidal or gum bleeding

6. Seropositive for HIV 1 or 2, or positive for hepatitis B surface antigen orhepatitis C virus (HCV) antibody.

7. Active, uncontrolled, systemic bacterial, fungal, or viral infections at Screening

8. Received strong CYP3A4 inhibitors or inducers

9. Received sunitinib within 3 weeks (Part 1a, Part 1b, DDI Substudy)